EGFR and non-small cell lung carcinoma: The discovery of activating mutations of the Epidermal Growth Factor Receptor (EGFR) gene, as well as the advancement of EGFR tyrosine kinase inhibitors (TKI), has had a significant impact on adaptive treatment strategies and, consequently, on survival among patients with advanced NSCLC [10].